Concord Biotech Ltd News

Antique maintains 'Buy' on Concord Biotech; sees strong API, CDMO growth

Antique expects the Concord to report revenue, Ebitda and PAT CAGR of 18 per cent, 17 per cent and 19 per cent, respectively, with margins remaining stable at around 42 per cent over FY25-28E

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Looking for dividend? Keep an eye on these 13 stocks today; check full list

Here is the complete list of stocks that will remain in focus today as they are set to trade ex-dividend tomorrow, Wednesday, September 3, 2025

Concord Biotech shares jump 6 per cent; here's what is fueling the gains

The upward movement in the pharmaceutical company's stock price followed an announcement regarding the company's Limbasi API facility

Looking to buy in falling market? NMDC, Godrej Agro, 2 others may gain 19%

NMDC, Godrej Agrovet, Amara Raja Energy and Concord Biotech witnessed a breakout on the daily chart in recent trading sessions; here's a likely technical outlook for these 4 stocks.

Concord Biotech rises 2% on incorporating its arm for marketing and sales

Concord Biotech share price rose 2.3 per cent, logging an intraday high at ₹1941.25 per share on the BSE after the company incorporated its subsidiary Concord Lifegen